Congratulations to my mentee Dr. @vpizzuti.bsky.social on this analysis of 2 years of PRO data in CAR-T recipients, now published @bloodjournals.hematology.org.
CAR-T confers long-term QoL benefits, and worsening patient-reported fatigue at D+15 may predict subsequent response as a "PRO-marker."
